Association of Probiotic Clostridium butyricum Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer
- 30 September 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 8 (10), 1236-1242
- https://doi.org/10.1158/2326-6066.CIR-20-0051
Abstract
Gut dysbiosis caused by antibiotics impairs response to immune checkpoint blockade (ICB). Gut microbiota is becoming an attractive therapeutic target for cancer. The Clostridium butyricum MIYAIRI 588 strain is a probiotic therapy used to improve symptoms related to antibiotic-induced dysbiosis in Japan. We hypothesized that probiotic Clostridium butyricum therapy (CBT) may affect the therapeutic efficacy of ICBs. We retrospectively evaluated 118 patients with advanced non-small cell lung cancer treated with ICBs at Kumamoto University Hospital (Kumamoto-shi, Kumamoto, Japan). Survival analysis comparing patients given CBT before and/or after ICB was conducted using univariate analyses and Cox proportional hazards regression models using propensity score. Propensity score analyses confirmed that probioticCBTsignificantly prolonged progression-free survival (PFS) and overall survival (OS). Probiotic CBT significantly associated with longer PFS and OS even in patients who received antibiotic therapy. This study suggests that probiotic CBT may have a positive impact on therapeutic efficacy of ICB in patients with cancer.Other Versions
Funding Information
- JSPS KAKENHI (JP18K15928)
This publication has 25 references indexed in Scilit:
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung CancerJAMA Oncology, 2018
- Gut microbiota modulate T cell trafficking into human colorectal cancerGut, 2018
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patientsScience, 2018
- Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumorsScience, 2018
- Effect of Clostridium�butyricum supplementation on the development of intestinal flora and the immune system of neonatal miceExperimental and Therapeutic Medicine, 2017
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacyScience, 2015
- The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitisSurgery Today, 2015
- Effect ofClostridium butyricumon fecal flora inHelicobacter pylorieradication therapyWorld Journal of Gastroenterology, 2005
- The effect of probiotic treatment withClostridium butyricumon enterohemorrhagicEscherichia coliO157:H7 infection in miceFEMS Immunology & Medical Microbiology, 2004
- Prevention of antibiotic‐associated diarrhea in children by Clostridium butyricum MIYAIRIPediatrics International, 2003